Navigation Links
Cyclosporine inhibits hepatitis C virus in vitro

Liver transplant patients with hepatitis C virus (HCV) achieved significantly better long-term viral response when taking the immunosuppressive agent Cyclosporine along with interferon-ribavirin combination therapy. Cyclosporine also showed efficacy against Hepatitis C virus in vitro.

The results of this study appear in the January 2006 issue of Liver Transplantation, the official journal of the American Association for the Study of Liver Diseases (AASLD) and the International Liver Transplantation Society (ILTS). The journal is published on behalf of the societies by John Wiley & Sons, Inc. and is available online via Wiley InterScience (

Hepatitis C always recurs after liver transplantation, often damaging the new organ and rendering patients ineligible for retransplantation. To address this problem, patients with hepatitis C often undergo interferon-ribavirin combination therapy after receiving a liver transplant in hopes of a sustained virologic response. At the same time, of course, the patients must take immunosuppressive agents to guard against transplant rejection.

The most commonly used anti-rejection medication is Tacrolimus, although Cyclosporine is also used. The latter drug has been shown to have anti-viral activity against HIV, herpes simplex and vaccinia virus, leading researchers to speculate it might also inhibit hepatitis C virus. To examine this hypothesis, they analyzed the impact of the drug in a liver transplant population. They also studied its effect on hepatitis C in vitro.

For the in vitro study, the researchers, led by Roberto J. Firpi, M.D. of the University of Florida, treated the HCV replicon line, GSB1, with varying doses of Cyclosporine for 48 hours and examined the results. They found that Cyclosporine reduced HCV replication by 20 percent, compared to no re duction with Tacrolimus. Furthermore, the Cyclosporine appeared to work through a different pathway compared to interferon.

Then, the researchers retrospectively examined the cases of 115 people infected with hepatitis C who had undergone liver transplantation at the University of Florida between 1991 and November 2002 and had received interferon-based therapy alongside their anti-rejection medications. After 48 weeks, 46 percent of the patients taking Cyclosporine had achieved a sustained virological response, compared with just 27 percent of the patients taking Tacrolimus.

"Our study suggests that Cyclosporine may play a beneficial role as primary immunosuppression for patients transplanted for HCV infection and may offer an advantage to Tacrolimus in those patients undergoing IFN-based therapy," the authors report. In addition, they confirm antiviral activity by the drug in cell cultures, having found that, "combination of Cyclosporine and interferon achieve better antiviral effect than either one alone."

Of note, considerably more patients taking Tacrolimus had to reduce or stop the therapy due to side effects. Also of possible significance, more patients taking Cyclosporine died, mostly due to infections and hepatitis complications, though this may be attributable to a longer follow-up period for that group.

Still, the indication that Cyclosporine had novel antiviral properties invites further investigation, the authors write. A prospective randomized comparative trial between cyclosporine and TAC should further evaluate their observations.

"Due to the accelerated rate of disease progression and graft failure after liver transplantation in HCV patients," the authors conclude, "it will be very important to determine the ideal immunosuppression regimen."


Source:John Wiley & Sons, Inc.

Related biology news :

1. Novel antiviral technology inhibits RSV infection in mice
2. Researchers find molecule that inhibits regrowth of spinal nerve cells
3. Techniques available to detect soil that inhibits destructive soybean pest
4. Chemical compound inhibits tumor growth, size in new mouse study
5. Dartmouth study finds that arsenic inhibits DNA repair
6. Viral hitchhiker inhibits Wolbachia bacterias ability to proliferate
7. Activation of microRNA inhibits cancer gene in human cancer cells
8. Study IDs protein that inhibits HIV from growing in cell cultures
9. Gene therapy inhibits epilepsy in animals
10. Antibiotic inhibits cancer gene activity
11. Multiple malaria infection inhibits spread of parasite
Post Your Comments:

(Date:11/17/2015)... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and ... of broadly enabling, pressure cycling technology ("PCT")-based sample preparation ... it has received gross proceeds of $745,000 from an ... "Offering"), increasing the total amount raised to date in ... are expected in the near future. ...
(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
(Date:11/4/2015)... 2015 --> ... by Transparency Market Research "Home Security Solutions Market - Global ... - 2022", the global home security solutions market is expected to ... The market is estimated to expand at a CAGR ... 2022. Rising security needs among customers at homes, the ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... DIEGO , Nov. 24, 2015 Halozyme Therapeutics, Inc. ... Healthcare Conference in New York on Wednesday, ... Helen Torley , president and CEO, will provide a corporate ... New York at 1:00 p.m. ET/10:00 a.m. PT ... and investor relations, will provide a corporate overview. --> ...
(Date:11/24/2015)...  Clintrax Global, Inc., a worldwide provider of clinical research services ... that the company has set a new quarterly earnings record in ... growth posted for Q3 of 2014 to Q3 of 2015.   ... , with the establishment of an Asia-Pacific ... United Kingdom and Mexico , ...
(Date:11/24/2015)... , November 24, 2015 ... market research report released by Transparency Market Research, the ... at a CAGR of 17.5% during the period between ... Market - Global Industry Analysis, Size, Volume, Share, Growth, ... non-invasive prenatal testing market to reach a valuation of ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... InSphero AG, ... 3D cell culture models, has promoted Melanie Aregger to serve as Chief Operating Officer. ... Aregger served on the management team and was promoted to Head of ...
Breaking Biology Technology: